Aligos Therapeutics Inc
ALGS7.590USD
+0.130+1.74%
交易中 （美東）報價延遲15分鐘
52.48M總市值
虧損本益比TTM
關於 Aligos Therapeutics Inc 公司
Aligos Therapeutics, Inc. 是一家臨牀階段的生物製藥公司，專注於開發新型療法，以滿足肝臟和病毒疾病中未滿足的醫療需求。該公司發現並開發代謝功能障礙相關脂肪性肝炎 (MASH) 和具有高度未滿足醫療需求的病毒（例如慢性乙型肝炎 (CHB) 和冠狀病毒）的療法。其用於 MASH 的高級候選藥物是 ALG-055009，一種小分子甲狀腺激素受體 β (THR-β) 激動劑。該公司還在推進用於 MASH 的寡核苷酸項目。該公司正在開發一系列差異化的 CHB 候選藥物，包括一種導致產生空病毒衣殼 (CAM-E) 的小分子衣殼組裝調節劑和程序性細胞死亡配體 1 (PD-1/PD-L1) 相互作用的小分子抑制劑。其第三個重點領域是開發具有泛冠狀病毒抗病毒活性的候選藥物。其管道包括 ALG-055009、ALG-000184、ALG-125755 和 ALG-097558。
公司簡介
公司代碼ALGS
公司名稱Aligos Therapeutics Inc
上市日期Oct 16, 2020
CEODr. Lawrence M. Blatt, Ph.D.
員工數量70
證券類型Ordinary Share
年結日Oct 16
公司地址One Corporate Dr., 2Nd Floor
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編94080
電話18004666059
網址https://www.aligos.com/
公司代碼ALGS
上市日期Oct 16, 2020
CEODr. Lawrence M. Blatt, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Lawrence M. Blatt, Ph.D.
Dr. Lawrence M. Blatt, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
84.82K
-1.34%
Dr. Julian A. Symons
Dr. Julian A. Symons
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
15.76K
-0.01%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
3.61K
--
Dr. K. Peter Hirth, Ph.D.
Dr. K. Peter Hirth, Ph.D.
Independent Director
Independent Director
--
--
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Mr. Jordyn Tarazi
Mr. Jordyn Tarazi
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Ms. Margarita Chavez, J.D.
Ms. Margarita Chavez, J.D.
Independent Director
Independent Director
--
--
Dr. Hardean E. Achneck
Dr. Hardean E. Achneck
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Dr. Bridget A. Martell, M.D.
Dr. Bridget A. Martell, M.D.
Independent Director
Independent Director
--
--
Dr. Heather Preston, M.D.
Dr. Heather Preston, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Lawrence M. Blatt, Ph.D.
Dr. Lawrence M. Blatt, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
84.82K
-1.34%
Dr. Julian A. Symons
Dr. Julian A. Symons
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
15.76K
-0.01%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
3.61K
--
Dr. K. Peter Hirth, Ph.D.
Dr. K. Peter Hirth, Ph.D.
Independent Director
Independent Director
--
--
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Mr. Jordyn Tarazi
Mr. Jordyn Tarazi
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Adage Capital Management, L.P.
8.75%
Deep Track Capital LP
8.36%
Roche Holding AG
8.30%
Alyeska Investment Group, L.P.
7.75%
Woodline Partners LP
5.93%
Other
60.91%
持股股東
持股股東
佔比
Adage Capital Management, L.P.
8.75%
Deep Track Capital LP
8.36%
Roche Holding AG
8.30%
Alyeska Investment Group, L.P.
7.75%
Woodline Partners LP
5.93%
Other
60.91%
股東類型
持股股東
佔比
Hedge Fund
44.95%
Investment Advisor
8.84%
Holding Company
8.30%
Investment Advisor/Hedge Fund
4.69%
Research Firm
3.41%
Individual Investor
2.14%
Venture Capital
0.19%
Other
27.47%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
98
3.84M
72.33%
+949.10K
2025Q1
107
3.92M
73.74%
+933.68K
2024Q4
102
2.24M
64.56%
-201.23K
2024Q3
108
2.31M
72.88%
-178.35K
2024Q2
119
2.51M
80.85%
+118.52K
2024Q1
173
2.47M
81.48%
-70.94K
2023Q4
186
2.43M
84.05%
+688.78K
2023Q3
190
1.29M
80.24%
-480.15K
2023Q2
195
1.32M
81.61%
-477.61K
2023Q1
201
1.36M
85.00%
-395.08K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Adage Capital Management, L.P.
465.00K
8.75%
+140.00K
+43.08%
Mar 31, 2025
Deep Track Capital LP
444.11K
8.36%
+200.00K
+81.93%
Mar 31, 2025
Roche Holding AG
441.04K
8.3%
-1.00
-0.00%
Mar 06, 2025
Alyeska Investment Group, L.P.
412.00K
7.75%
+412.00K
--
Mar 31, 2025
Woodline Partners LP
315.38K
5.93%
+315.38K
--
Mar 31, 2025
Heights Capital Management, Inc.
241.50K
4.54%
+241.50K
--
Mar 31, 2025
Hudson Bay Capital Management LP
241.50K
4.54%
+241.50K
--
Mar 31, 2025
Sio Capital Management, LLC
180.72K
3.4%
+180.72K
--
Mar 31, 2025
BofA Global Research (US)
154.50K
2.91%
+154.22K
+54111.58%
Mar 31, 2025
Tang Capital Management, LLC
141.13K
2.66%
+141.13K
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Schwab U.S. Small-Cap ETF
0%
Schwab U.S. Broad Market ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Schwab U.S. Small-Cap ETF
佔比0%
Schwab U.S. Broad Market ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
DFA Dimensional US Core Equity Market ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Aug 15, 2024
Merger
25<1
Aug 15, 2024
Merger
25<1
Aug 15, 2024
Merger
25<1
Aug 15, 2024
Merger
25<1
公告日期
類型
比率
Aug 15, 2024
Merger
25<1
Aug 15, 2024
Merger
25<1
Aug 15, 2024
Merger
25<1
Aug 15, 2024
Merger
25<1
